NARI - Inari Medical Inc Stock Price, Fair Value and News

39.08USD-0.41 (-1.04%)Delayed

Market Summary

USD39.08-0.41

Delayed

-1.04%

NARI Alerts

2 major insider sales recently.

NARI Stock Price

View Fullscreen

NARI RSI Chart

NARI Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-1.4K

Price/Sales (Trailing)

4.59

EV/EBITDA

196.48

Price/Free Cashflow

72.56

NARI Price/Sales (Trailing)

NARI Profitability

EBT Margin

0.86%

Return on Equity

-0.35%

Return on Assets

-0.24%

Free Cashflow Yield

1.38%

NARI Fundamentals

NARI Revenue

Revenue (TTM)

493.6M

Rev. Growth (Yr)

22.57%

Rev. Growth (Qtr)

4.53%

NARI Earnings

Earnings (TTM)

-1.6M

Earnings Growth (Yr)

19.54%

Earnings Growth (Qtr)

-247.53%

Breaking Down NARI Revenue

Last 7 days

-9.5%

Last 30 days

-3.9%

Last 90 days

-32.8%

Trailing 12 Months

-40.2%

How does NARI drawdown profile look like?

NARI Financial Health

Current Ratio

3.09

NARI Investor Care

Shares Dilution (1Y)

6.71%

Diluted EPS (TTM)

-0.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	412.9M	439.1M	469.3M	493.6M
2022	306.3M	335.6M	358.9M	383.5M
2021	170.1M	208.2M	242.4M	277.0M
2020	71.1M	86.5M	110.9M	139.7M
2019	0	21.6M	36.4M	51.1M
2018	0	0	0	6.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Inari Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 12, 2024	hill, mitch c.	sold	-245,760	40.96	-6,000	chief financial officer
Apr 12, 2024	hill, mitch c.	acquired	2,742	0.457	6,000	chief financial officer
Apr 01, 2024	hoffman william	sold (taxes)	-	-	-2,063	-
Apr 01, 2024	hykes andrew	sold (taxes)	-	-	-4,222	president and ceo
Apr 01, 2024	tu thomas	sold (taxes)	-	-	-2,119	chief medical officer
Apr 01, 2024	hill, mitch c.	sold (taxes)	-	-	-2,067	chief financial officer
Mar 18, 2024	hoffman william	sold	-1,645,080	41.127	-40,000	-
Mar 12, 2024	hill, mitch c.	sold	-251,461	41.9101	-6,000	chief financial officer
Mar 12, 2024	hill, mitch c.	acquired	2,742	0.457	6,000	chief financial officer
Feb 16, 2024	hykes andrew	acquired	-	-	40,786	president and ceo

Which funds bought or sold NARI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	Legato Capital Management LLC	sold off	-100	-1,004,900	-	-%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	reduced	-25.75	-177,703	216,102	-%
Apr 15, 2024	PFS Partners, LLC	unchanged	-	-660	1,872	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	new	-	698,397	698,397	0.02%
Apr 12, 2024	First PREMIER Bank	new	-	8,000	8,000	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	reduced	-83.33	-1,708	240	-%
Apr 05, 2024	GAMMA Investing LLC	added	192	7,581	12,763	-%
Apr 05, 2024	CWM, LLC	reduced	-96.97	-2,840,000	65,000	-%
Apr 02, 2024	M&R CAPITAL MANAGEMENT INC	sold off	-100	-1,428	-	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-30.14	-38,112	86,213	-%

Are Funds Buying or Selling NARI?

Are funds buying NARI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NARI

No. of Funds

NARI Alerts

2 major insider sales recently.

Unveiling Inari Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 03, 2024	millennium management llc	3.8%	2,181,337	SC 13G
Feb 14, 2024	point72 asset management, l.p.	1.2%	668,429	SC 13G/A
Feb 13, 2024	vanguard group inc	8.75%	5,038,292	SC 13G/A
Feb 08, 2024	wellington management group llp	7.92%	4,563,325	SC 13G/A
Feb 08, 2024	milder donald b	5.4%	3,084,302	SC 13G/A
Jan 24, 2024	blackrock inc.	11.6%	6,696,598	SC 13G/A
Feb 24, 2023	point72 asset management, l.p.	4.9%	2,611,241	SC 13G
Feb 14, 2023	macquarie group ltd	3.38%	1,814,852	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	4.1%	2,183,673	SC 13G/A
Feb 13, 2023	capital international investors	0.1%	72,099	SC 13G/A

Recent SEC filings of Inari Medical Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	SC 13G	Major Ownership Report
Mar 20, 2024	4	Insider Trading
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	4	Insider Trading

Peers (Alternatives to Inari Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	189.6B	40.1B	-5.40%	4.53%	33.12	4.73	-8.12%	-17.45%
BDX	66.7B	19.5B	-2.42%	-9.87%	53.13	3.42	4.02%	-22.04%
ALGN	22.9B	3.9B	-2.94%	-12.25%	51.49	5.93	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.36	2.12%	209.17%
MID-CAP
HSIC	9.2B	12.3B	-4.49%	-14.03%	22	0.74	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.41	3.2	-4.68%	82.43%
XRAY	6.4B	4.0B	-6.21%	-24.72%	-47.49	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-565.58	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.0M	166.7M	0.59%	-11.05%	-4.6	2.28	6.67%	-456.34%
ANGO	260.4M	324.0M	21.04%	-28.41%	-1.35	0.8	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

Inari Medical Inc News

Latest updates

Inari Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	4.5%	132,094	126,366	119,005	116,167	107,771	96,204	92,744	86,752	83,218	72,916	63,453	57,397	48,611	38,715	25,392	26,953	19,887	14,225	10,072	-
Gross Profit	2.9%	115,088	111,889	105,161	102,426	94,643	85,140	82,397	76,785	74,938	65,876	58,639	52,774	44,925	35,487	21,905	24,247	17,748	12,715	8,741	-
Operating Expenses	13.3%	124,385	109,776	106,671	107,764	100,534	94,938	91,725	79,867	73,192	68,603	54,527	45,061	37,929	28,297	22,508	19,411	16,578	11,822	9,383	-
S&GA Expenses	15.0%	101,493	88,284	85,586	85,700	80,122	75,833	73,156	63,732	54,466	56,104	42,897	36,898	31,393	23,080	18,880	16,393	13,869	10,100	7,803	-
R&D Expenses	6.5%	22,892	21,492	21,085	22,064	20,412	19,105	18,569	16,135	18,726	12,499	11,630	8,163	6,536	5,217	3,628	3,018	2,709	1,722	1,580	-
EBITDA Margin	30.7%	0.02*	0.02*	-0.02*	-0.05*	-0.06*	-0.04*	-0.03*	0.01*	0.05*	0.08*	0.13*	0.12*	-	-	-	-	-	-	-	-
Interest Expenses	60.5%	69.00	43.00	44.00	40.00	74.00	74.00	73.00	73.00	75.00	73.00	74.00	73.00	75.00	251	463	346	238	226	229	-
Income Taxes	-38.6%	1,491	2,428	939	1,024	990	840	1,252	-	574	61.00	12.00	198	-	-	-	-	-11.00	1.00	-	-
Earnings Before Taxes	-156.8%	-3,174	5,590	3,024	-1,194	-4,808	-9,313	-8,935	-3,129	1,681	-2,743	4,080	7,667	6,985	6,496	-3,804	4,112	-	-	-	-
EBT Margin	54.5%	0.01*	0.01*	-0.03*	-0.06*	-0.07*	-0.05*	-0.04*	0.00*	0.04*	0.07*	0.12*	0.10*	-	-	-	-	-	-	-	-
Net Income	-247.5%	-4,665	3,162	2,085	-2,218	-5,798	-10,153	-10,187	-3,129	1,107	-2,804	4,068	7,469	6,985	6,496	-3,804	4,112	355	366	-965	-
Net Income Margin	43.8%	0.00*	-0.01*	-0.04*	-0.07*	-0.08*	-0.06*	-0.04*	0.00*	0.04*	0.06*	0.12*	0.10*	-	-	-	-	-	-	-	-
Free Cashflow	-20.9%	11,332	14,331	8,531	-2,977	9,477	-15,375	-6,180	-11,845	12,289	-10,330	2,381	7,501	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	22.8%	674	549	525	507	504	488	484	484	312	292	254	235	214	206	224	45.00
Current Assets	-49.8%	236	469	445	426	423	411	411	413	245	228	228	221	206	199	220	39.00
Cash Equivalents	-56.7%	39.00	89.00	58.00	57.00	60.00	84.00	80.00	187	93.00	81.00	91.00	103	115	24.00	195	24.00
Inventory	6.6%	43.00	40.00	39.00	36.00	33.00	30.00	27.00	24.00	21.00	19.00	18.00	14.00	11.00	7.00	6.00	4.00
Net PPE	-1.5%	21.00	21.00	21.00	21.00	22.00	21.00	20.00	18.00	16.00	15.00	11.00	7.00	7.00	5.00	4.00	3.00
Goodwill	-	214	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	116.5%	209	97.00	89.00	80.00	87.00	73.00	70.00	65.00	72.00	58.00	32.00	21.00	14.00	14.00	40.00	30.00
Current Liabilities	15.5%	76.00	66.00	58.00	48.00	56.00	42.00	41.00	36.00	43.00	30.00	32.00	21.00	14.00	14.00	11.00	9.00
Shareholder's Equity	2.8%	465	452	436	427	417	415	414	419	239	234	222	214	200	191	184	-
Retained Earnings	-10.6%	-48.49	-43.82	-46.98	-49.07	-46.85	-41.05	-30.90	-20.71	-17.58	-18.69	-15.89	-19.95	-27.42	-34.41	-40.90	-41.21
Additional Paid-In Capital	1.5%	504	497	484	476	463	457	446	440	257	253	238	234	228	226	225	2.00
Shares Outstanding	0.4%	58.00	58.00	57.00	57.00	54.00	53.00	53.00	51.00	50.00	50.00	50.00	49.00	-	-	-	-
Float	-	-	-	2,830	-	-	-	3,280	-	-	-	3,950	-	-	-	954	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-23.2%	12,241	15,939	9,760	-2,013	11,255	-13,066	-3,061	-9,100	15,007	-5,589	7,302	8,766	-1,624	5,341	-1,126	-679	-826	-335	-	-
Share Based Compensation	-0.4%	9,801	9,844	10,353	10,339	7,596	7,356	7,164	6,555	4,509	12,499	4,604	3,836	1,565	959	506	494	176	139	-	-
Cashflow From Investing	-605.2%	-59,716	11,821	-6,080	-4,043	-33,247	13,402	-101,860	-73,511	-2,657	-7,428	-18,426	-22,511	-52,361	-1,658	-809	-609	-1,082	-1,163	-	-
Cashflow From Financing	-169.5%	-2,410	3,467	-2,352	2,466	-1,689	3,880	-1,595	176,542	-620	2,993	-514	2,214	226	-30,531	164,398	10,022	10,025	178	-	-

NARI Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 493,632	$ 383,471	$ 276,984
Cost of goods sold	59,068	44,506	24,757
Gross profit	434,564	338,965	252,227
Operating expenses
Research and development	87,533	74,221	51,018
Selling, general and administrative	361,063	292,843	190,365
Total operating expenses	448,596	367,064	241,383
(Loss) income from operations	(14,032)	(28,099)	10,844
Other income (expense)
Interest income	15,613	1,852	154
Interest expense	(196)	(294)	(295)
Other income (expense)	2,861	356	(18)
Total other income (expense)	18,278	1,914	(159)
Income (loss) before income taxes	4,246	(26,185)	10,685
Provision for income taxes	5,882	3,082	845
Net (loss) income	(1,636)	(29,267)	9,840
Other comprehensive income (loss)
Foreign currency translation adjustments	9,864	(592)	(379)
Unrealized loss (gain) on available-for-sale debt securities	(1,828)	1,843	(27)
Total other comprehensive income (loss)	8,036	1,251	(406)
Comprehensive income (loss)	$ 6,400	$ (28,016)	$ 9,434
Net (loss) income per share
Basic (in dollars per share)	$ (0.03)	$ (0.55)	$ 0.20
Diluted (in dollars per share)	$ (0.03)	$ (0.55)	$ 0.18
Weighted average common shares used to compute net (loss) income per share
Basic (in shares)	56,770,657	52,837,674	49,815,914
Diluted (in shares)	56,770,657	52,837,674	55,594,159

NARI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 38,597,000	$ 60,222,000
Restricted cash	611,000	0
Short-term investments in debt securities	76,855,000	266,179,000
Accounts receivable, net	70,119,000	58,611,000
Inventories, net	42,900,000	32,581,000
Prepaid expenses and other current assets	6,481,000	5,312,000
Total current assets	235,563,000	422,905,000
Property and equipment, net	20,929,000	21,655,000
Operating lease right-of-use assets	48,407,000	50,703,000
Goodwill	214,335,000	0
Intangible assets	150,884,000	0
Deposits and other assets	4,117,000	8,889,000
Total assets	674,235,000	504,152,000
Current liabilities
Accounts payable	10,577,000	7,659,000
Payroll-related accruals	48,706,000	38,955,000
Accrued expenses and other current liabilities	15,364,000	8,249,000
Operating lease liabilities, current portion	1,692,000	1,311,000
Total current liabilities	76,339,000	56,174,000
Operating lease liabilities, noncurrent portion	30,355,000	30,976,000
Deferred tax liability	36,231,000	0
Other long-term liability	66,400,000	0
Total liabilities	209,325,000	87,150,000
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized as of December 31, 2023 and 2022; 57,762,414 and 54,021,656 shares issued and outstanding as of December 31, 2023 and 2022, respectively	58,000	54,000
Additional paid in capital	504,453,000	462,949,000
Accumulated other comprehensive income	8,885,000	849,000
Accumulated deficit	(48,486,000)	(46,850,000)
Total stockholders' equity	464,910,000	417,002,000
Total liabilities and stockholders' equity	$ 674,235,000	$ 504,152,000

About Inari Medical Inc

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. The company provides ClotTriever, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

CEO	Mr. Andrew J. Hykes
WEBSITE	inarimedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1100

Inari Medical Inc Frequently Asked Questions

What is the ticker symbol for Inari Medical Inc? What does NARI stand for in stocks?

NARI is the stock ticker symbol of Inari Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Inari Medical Inc (NARI)?

As of Tue Apr 16 2024, market cap of Inari Medical Inc is 2.27 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NARI stock?

You can check NARI's fair value in chart for subscribers.

What is the fair value of NARI stock?

You can check NARI's fair value in chart for subscribers. The fair value of Inari Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Inari Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NARI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Inari Medical Inc a good stock to buy?

The fair value guage provides a quick view whether NARI is over valued or under valued. Whether Inari Medical Inc is cheap or expensive depends on the assumptions which impact Inari Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NARI.

What is Inari Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, NARI's PE ratio (Price to Earnings) is -1384.53 and Price to Sales (PS) ratio is 4.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NARI PE ratio will change depending on the future growth rate expectations of investors.